Nutriband subsidiary, 4p therapeutics llc, conducts phase 1b clinical study for sorrento therapeutics, inc. on lymphatic etanercept delivery in rheumatoid arthritis patients with results to be presented at the 2022 american college of rheumatology confere

Orlando, fl / accesswire / october 26, 2022 / nutriband inc. (the "company") (nasdaq:ntrb) (nasdaq:ntrbw) today announced that its subsidiary, 4p therapeutics llc ("4p therapeutics"), has conducted a phase 1b clinical study for sorrento therapeutics, inc. ("sorrento") (nasdaq:srne) with results to be presented at the american college of rheumatology (acr) convergence 2022 conference on november 13, 2022 as a poster abstract entitled "lymphatic delivery of etanercept achieves significant improvements in rheumatoid arthritis disease measures at 50% of the standard dose for patients with an inadequate response to subcutaneous injections." "we are excited about these proof of concept clinical results and the development of sorrento's sofusa lymphatic delivery platform for treatment of autoimmune diseases such as rheumatoid arthritis to provide hope for those patients who do not respond adequately to conventional biologic injections," said alan smith, ph.d.
NTRB Ratings Summary
NTRB Quant Ranking